Decoy receptor 3 (DcR3)/TR6/M68 is a soluble receptor that binds to the Fas ligand LIGHT and TL1A. Elevated levels of DcR3 expression have been found in many tumors. We report an unexpected effect of DcR3 by sensitizing Jurkat and U937 cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cell death triggered by anti-Fas and tumor necrosis factor was unaffected by DcR3. DcR3 by itself did not stimulate apoptosis. The ability to augment TRAIL-initiated cell death was not observed with soluble lymphotoxin  receptor or soluble death receptor 3, indicating that binding to LIGHT or TL1A alone is insufficient to trigger TRAIL sensitivity. Incubation with DcR3 did not increase the surface expression of TRAIL receptor, and the level of Fas-associated death domain protein and cellular FLICE-like inhibitory protein was not altered. Instead, in the presence of DcR3, TRAIL engagement resulted in an increased activation of caspase-8, an elevated cleavage of Bid, and enhanced release of Smac and cytochrome c from mitochondria to cytosol compared with TRAIL alone. This led to increased activation of caspase-9 and caspase-3. The unusual ability of DcR3 to promote TRAIL-triggered death may be used to potentiate TRAIL efficacy during treatment tumors overexpressing DcR3.
Decoy receptor 3 (DcR3)1 /TR6/M68 is a member of the tumor necrosis factor receptor superfamily (1). DcR3 binds to at least three different ligands: Fas ligand (FasL), LIGHT, and TL1A (1-3). The biological functions initiated by these three ligands are blocked by the presence of DcR3. DcR3 is overexpressed in primary lung and colon tumors (1), in gliomas (4), gastrointestinal tract tumors (5, 6), autoimmune tissues (7), and virusassociated leukemia (8). It has been suggested that DcR3 acts as a decoy receptor for tumor cells to neutralize the cytotoxic and regulatory effects of FasL, LIGHT, and TL1A, in that inoculation of rats with glioma cells overexpressing DcR3 resulted in decreased infiltration of T cells and macrophages (4).DcR3 has also been shown to promote angiogenesis through neutralization of TL1A (9).Recent studies have revealed the profound modulatory effects of DcR3 on many cells. DcR3 regulates CD14 ϩ monocyte differentiation into dendritic cells, with down-regulation of HLA-DR, CD56/ICAM-1, and CD80, and up-regulation of CD86 in mature dendritic cells, leading to skewed Th2 differentiation in primed T cells (10). DcR3 attenuates T cell activation and reduces T cell response to mouse heart allograft (11). DcR3 also decreases T cell interaction with antigen-presenting cells (12) and inhibits T cell chemotaxis (13). In addition, DcR3 triggers actin re-organization, increases the adhesion of monocytes (14), and reduces phagocytic activity and proinflammatory cytokine production in macrophages (15).TRAIL induces apoptosis by binding to TRAIL receptor (16, 17). There are five different TRAIL receptors, including TRAIL-R1/DR4, TRAIL-R2/DR5, TRAIL-R3/DcR1, TRAIL-R4/ DcR2, and osteoprotegerin. Binding of DR4 and DR...